News
HpVac Appoints Joana Vitte, MD, PhD, as Chief Scientific Officer
– Significant expansion of allergy research expertise
HpVac SA, a company developing novel preventive and therapeutic first-line therapies against allergic and inflammatory diseases, today announced that Joana Vitte, MD, PhD, Habil. will be joining HpVac as Chief Scientific Officer.
Joana Vitte is an experienced scientist with a strong track record in allergy diagnostics and clinical research. She brings significant knowledge in human immunology, flow cytometry, and allergy testing. Among others, her work focuses on the interplay of allergic and anti-infectious immune responses. Joana Vitte has a joint position as Associate Professor of Immunology at Aix-Marseille University and the University Hospital of Marseille and is also Associate Researcher at the Institut d’Épidémiologie et de Santé Publique (IDESP) of the University of Montpellier. She is also Vice President for science and education at the French Society of Allergology.
Dopavision Appoints Dr. Dirk Sauer as Chair of the Company’s Advisory Board
– Former Head of Novartis’ Ophthalmology Development Unit to provide significant product development expertise and industry network
Dopavision, a clinical-stage company pioneering the development of digital therapeutics, today announced the appointment of Dr. Dirk Sauer as Chairman of the Company’s Advisory Board. Dirk Sauer brings an exceptional track record in the development of ophthalmic therapeutics and an extensive industry network to advance MyopiaX®, Dopavision’s leading-edge digital therapeutic for childhood myopia control. MyopiaX® is currently in clinical trials in Germany, Portugal, Spain, and Ireland.
ImmunOs Therapeutics´ Lead Program Shows Strong Anti-Tumor Activity In Vivo and In Vitro
– Promising data presented at Protein and Antibody Engineering Summit (PEGS)
– Multi-functional agent targeting three immune checkpoint receptors
– Potential as mono- and combination therapy for solid tumors and blood cancers
ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced promising data for the Company´s lead program IOS-1002. Read more…
T-knife Therapeutics Announces Dosing of First Patient with TK-8001 in the IMAG1NE Phase 1/2 Clinical Trial
– The IMAG1NE Phase 1/2 trial is an accelerated dose-titration, open-label, multi-center Phase 1/2 trial to evaluate TK-8001 in patients with MAGE-A1 positive solid tumors
– TK-8001 targets a MAGE-A1 epitope presented on HLA-A*02:01
– IMAG1NE utilizes biomarker-guided patient selection criteria to enroll those patients that have the highest potential for safe, deep, and durable responses
– MAGE-A1 is an attractive therapeutic target that is highly cancer specific and demonstrates significant consistency of expression between primary tumor and metastases
T-knife Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing T cell receptor-based immunotherapies that deliver transformational benefits to cancer patients, today announced it has dosed the first patient in the IMAG1NE Phase 1/2 clinical trial.